Payment-Scheme

29Jan 2019

Value-based pact serves up Brilinta at generic-level copays (AstraZeneca)

Cardiovascular Diseases, Health Outcomes, Insurance, Medicare, Payment-Scheme, Reimbursement, USA, Value Based Contracting

FiercePharma, by Carly Helfand, Jan 28, 2019 AstraZeneca has struck a deal with UPMC Health Plan (USA) that links reimbursement for the blood thinner, which is approved to cut the risk of death or a second heart attack in people who have already had one, to patients’ cardiovascular outcomes—the usual trade-off for a value-based deal. But […]

29Jan 2019

Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies (Novartis)

Cost-effectiveness, Gene Therapy, Health Technology Assessment, Healthcare Cost, ICER, Pay for performance, Payment-Scheme, Pricing, USA, Value

FiercePharma, by Arlene Weintraub, Jan 29, 2019 When Dave Lennon, president of Novartis unit AveXis, said in November that the company’s experimental gene therapy to treat spinal muscular atrophy (SMA) could be cost-effective at a price of $4 million to $5 million, some pricing critics immediately raised red flags. But then the Institute for Clinical […]